TransCode Therapeutics Inc. Common Stock is a biotechnology business based in the US. TransCode Therapeutics IncCommon Stock shares (RNAZ) are listed on the NASDAQ and all prices are listed in US Dollars. TransCode Therapeutics IncCommon Stock employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $2.27 |
|---|---|
| 52-week range | $2.35 - $7.00 |
| 50-day moving average | $2.71 |
| 200-day moving average | $2.94 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.76 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.27 from 2022-01-19
| 1 week (2022-01-14) | -9.56% |
|---|---|
| 1 month (2021-12-21) | -8.84% |
| 3 months (2021-10-21) | -20.07% |
| 6 months (2021-07-21) | -31.42% |
| 1 year (2021-01-17) | N/A |
|---|---|
| 2 years (2020-01-17) | N/A |
| 3 years (2019-01-17) | N/A |
| 5 years (2017-01-17) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -16.7% |
| Return on equity TTM | -47.19% |
| Profit margin | 0% |
| Book value | $1.80 |
| Market capitalisation | $32.4 million |
TTM: trailing 12 months
We're not expecting TransCode Therapeutics IncCommon Stock to pay a dividend over the next 12 months.
TransCode Therapeutics, Inc. , a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts. .
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.